



## Antifungal Formulary: Consensus and Controversies

This program is an overview of the pathophysiology, diagnosis, and treatment of invasive fungal infections.

### Educational Objectives

At the conclusion of the program, participants will be able to:

- Understand the etiology, incidence, and procedures used for diagnosis of invasive fungal infections
- Compare and contrast the spectrum, biopharmaceutical properties, and role of the newer triazoles and echinocandin antifungal agents
- Assess the strengths and limitations of current treatment approaches and guidelines for the management of candidiasis and mould infections
- Discuss combination and salvage therapy strategies for patients who fail to respond to first-line antifungal agents

### Accreditation



TG Medical Education, LLC is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing education and complies with the Criteria for continuing pharmacy education programming. This program provides 1.0 hour (0.1 CEU) of continuing pharmacy education credit (ACPE Universal Program Number 454-999-06-004-H01). The original program release date is April 3, 2007.

### Statement of Credit

Following the successful completion of this course and post-test, participants will receive their Statement of Credit, which is available for printing. TG Medical Education does not mail Statements of Credit for its online content. Prior to completing the online program, please make sure that your computer is hooked-up to a working printer.

### Intended Audience

This educational activity is intended for pharmacists who care for patients at risk for antifungal infections.

### Support

This program is supported by an educational grant from Astellas Pharma US. There is no fee for this program.

### Program Faculty

- **Faculty Disclosure Statement** In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, TG Medical Education requires that faculty members disclose any relationship (e.g., shareholder, recipient of research grant, consultant, or member of an advisory committee) that the faculty may have with commercial companies whose products or services may be mentioned in their presentations. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on faculty presentations.
- **Faculty and Disclosure Information** Russell E. Lewis, PharmD, FCCP, BCPS—Associate Professor, University of Houston College of Pharmacy/The University of Texas MD Anderson Cancer Center.
  - Grant/Research Support: Astellas Pharma US; Enzon Pharmaceuticals; Merck & Company
  - Consultant: Astellas Pharma US; Enzon Pharmaceuticals; Schering-Plough
  - Speaker with Honorarium: Astellas Pharma US; Enzon Pharmaceuticals; Merck & Company
- Does not plan to discuss unlabeled/investigational uses of a commercial product.